Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03819634 · ClinicalTrials.gov registry record · NA
Longevity of Multi-Slitted Catheter With Lantern Technology
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT03819634: Completed NA study, sponsored by Stanford University.
NCT03819634 is a NA study that has completed, run by Stanford University. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03819634, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
To determine time to set failure when the Convatec Inset II with Lantern technology (Convatec Lantern) infusion set with multi-slitted catheter is worn for up to 10 days
Primary Outcome
Time to when the infusion set fails and needs to be replaced.
Interventions
- DEVICE Inset II with Lantern Technology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2019-04-20 |
| Phase | NA |
What the finished NCT03819634 record still lists
NCT03819634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Inset II with Lantern Technology is the first listed.
NCT03819634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03819634 about?
NCT03819634 is a clinical study titled "Longevity of Multi-Slitted Catheter With Lantern Technology". To determine time to set failure when the Convatec Inset II with Lantern technology (Convatec Lantern) infusion set with multi-slitted catheter is worn for up to 10 days
What is the current status of trial NCT03819634?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2019-01-25. Estimated completion is 2019-04-20.
What interventions are being tested in trial NCT03819634?
The interventions under investigation include: Inset II with Lantern Technology (DEVICE).
Who is sponsoring clinical trial NCT03819634?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03819634's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI